Literature DB >> 34937950

Pembrolizumab for HER2+ gastric cancer.

David Killock1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34937950     DOI： 10.1038/s41571-021-00594-x

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Authors:  Yelena Y Janjigian; Akihito Kawazoe; Patricio Yañez; Ning Li; Sara Lonardi; Oleksii Kolesnik; Olga Barajas; Yuxian Bai; Lin Shen; Yong Tang; Lucjan S Wyrwicz; Jianming Xu; Kohei Shitara; Shukui Qin; Eric Van Cutsem; Josep Tabernero; Lie Li; Sukrut Shah; Pooja Bhagia; Hyun Cheol Chung
Journal:  Nature       Date:  2021-12-15       Impact factor: 69.504
  1 in total
  1 in total

Review 1.  The Role of the Heat-Shock Proteins in Esophagogastric Cancer.

Authors:  Francisco Tustumi; Gabriel Andrade Agareno; Ricardo Purchio Galletti; Rafael Benjamim Rosa da Silva; Julia Grams Quintas; Lucas de Abreu Sesconetto; Daniel José Szor; Nelson Wolosker
Journal:  Cells       Date:  2022-08-27       Impact factor: 7.666
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.